Cost and effectiveness of reduced-intensity and conventional allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome

Osamu Imataki, Takeshi Kamioka, Takashi Fukuda, Ryuji Tanosaki, Yoichi Takaue

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Goals of work: Allogeneic stem cell transplantation with a reduced-intensity regimen (RIST) has been evaluated mostly in terms of its clinical benefit, and the pharmacoeconomic aspects of this procedure remain unclear. We compared the cost and effectiveness of RIST with those of stem cell transplantation using a conventional myeloablative regimen (CST). Patients and methods: Fifty consecutive patients who underwent transplantation for myeloid malignancy were included. Life years and medical costs during the entire treatment course for up to 2 years after transplantation were evaluated, and cost-effectiveness was assessed from the payer's perspective. Main results: Of these 50 cases, 35 were treated with CST and 15 were treated with RIST. The mean survival time was 1.5 years in CST and 1.2 years in RIST, while the mean total cost per patient within the first 2 years was 29,630 for CST and 29,466 for RIST, with no significant difference. The duration of total hospitalization was shorter in RIST than in CST; then, the cost for hospitalization represented a lower proportion of the total cost in RIST (49% of total cost) than in CST (63%). In contrast, the cost related to the conditioning regimen was significantly higher in RIST than in CST. Conclusions: This result suggests that the increased cost of the conditioning regimen offsets the reduced cost of hospitalization in RIST. Although some differences were observed in the details of the cost, the total cost and mean survival were comparable between CST and RIST, and this result was confirmed by a probabilistic sensitivity analysis.

Original languageEnglish
Pages (from-to)1565-1569
Number of pages5
JournalSupportive Care in Cancer
Volume18
Issue number12
DOIs
Publication statusPublished - 2010 Dec
Externally publishedYes

Fingerprint

Hematopoietic Stem Cell Transplantation
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Cost-Benefit Analysis
Costs and Cost Analysis
Hospitalization
Stem Cell Transplantation
Transplantation
Pharmaceutical Economics
Survival Rate
Survival

Keywords

  • Allogeneic stem cell transplantation (allo-SCT)
  • Cost-effective analysis (CEA)
  • Medical economics

ASJC Scopus subject areas

  • Oncology

Cite this

Cost and effectiveness of reduced-intensity and conventional allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. / Imataki, Osamu; Kamioka, Takeshi; Fukuda, Takashi; Tanosaki, Ryuji; Takaue, Yoichi.

In: Supportive Care in Cancer, Vol. 18, No. 12, 12.2010, p. 1565-1569.

Research output: Contribution to journalArticle

@article{810b6bb01f8e4fe9935ea8b29ad23242,
title = "Cost and effectiveness of reduced-intensity and conventional allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome",
abstract = "Goals of work: Allogeneic stem cell transplantation with a reduced-intensity regimen (RIST) has been evaluated mostly in terms of its clinical benefit, and the pharmacoeconomic aspects of this procedure remain unclear. We compared the cost and effectiveness of RIST with those of stem cell transplantation using a conventional myeloablative regimen (CST). Patients and methods: Fifty consecutive patients who underwent transplantation for myeloid malignancy were included. Life years and medical costs during the entire treatment course for up to 2 years after transplantation were evaluated, and cost-effectiveness was assessed from the payer's perspective. Main results: Of these 50 cases, 35 were treated with CST and 15 were treated with RIST. The mean survival time was 1.5 years in CST and 1.2 years in RIST, while the mean total cost per patient within the first 2 years was 29,630 for CST and 29,466 for RIST, with no significant difference. The duration of total hospitalization was shorter in RIST than in CST; then, the cost for hospitalization represented a lower proportion of the total cost in RIST (49{\%} of total cost) than in CST (63{\%}). In contrast, the cost related to the conditioning regimen was significantly higher in RIST than in CST. Conclusions: This result suggests that the increased cost of the conditioning regimen offsets the reduced cost of hospitalization in RIST. Although some differences were observed in the details of the cost, the total cost and mean survival were comparable between CST and RIST, and this result was confirmed by a probabilistic sensitivity analysis.",
keywords = "Allogeneic stem cell transplantation (allo-SCT), Cost-effective analysis (CEA), Medical economics",
author = "Osamu Imataki and Takeshi Kamioka and Takashi Fukuda and Ryuji Tanosaki and Yoichi Takaue",
year = "2010",
month = "12",
doi = "10.1007/s00520-009-0779-z",
language = "English",
volume = "18",
pages = "1565--1569",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "12",

}

TY - JOUR

T1 - Cost and effectiveness of reduced-intensity and conventional allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome

AU - Imataki, Osamu

AU - Kamioka, Takeshi

AU - Fukuda, Takashi

AU - Tanosaki, Ryuji

AU - Takaue, Yoichi

PY - 2010/12

Y1 - 2010/12

N2 - Goals of work: Allogeneic stem cell transplantation with a reduced-intensity regimen (RIST) has been evaluated mostly in terms of its clinical benefit, and the pharmacoeconomic aspects of this procedure remain unclear. We compared the cost and effectiveness of RIST with those of stem cell transplantation using a conventional myeloablative regimen (CST). Patients and methods: Fifty consecutive patients who underwent transplantation for myeloid malignancy were included. Life years and medical costs during the entire treatment course for up to 2 years after transplantation were evaluated, and cost-effectiveness was assessed from the payer's perspective. Main results: Of these 50 cases, 35 were treated with CST and 15 were treated with RIST. The mean survival time was 1.5 years in CST and 1.2 years in RIST, while the mean total cost per patient within the first 2 years was 29,630 for CST and 29,466 for RIST, with no significant difference. The duration of total hospitalization was shorter in RIST than in CST; then, the cost for hospitalization represented a lower proportion of the total cost in RIST (49% of total cost) than in CST (63%). In contrast, the cost related to the conditioning regimen was significantly higher in RIST than in CST. Conclusions: This result suggests that the increased cost of the conditioning regimen offsets the reduced cost of hospitalization in RIST. Although some differences were observed in the details of the cost, the total cost and mean survival were comparable between CST and RIST, and this result was confirmed by a probabilistic sensitivity analysis.

AB - Goals of work: Allogeneic stem cell transplantation with a reduced-intensity regimen (RIST) has been evaluated mostly in terms of its clinical benefit, and the pharmacoeconomic aspects of this procedure remain unclear. We compared the cost and effectiveness of RIST with those of stem cell transplantation using a conventional myeloablative regimen (CST). Patients and methods: Fifty consecutive patients who underwent transplantation for myeloid malignancy were included. Life years and medical costs during the entire treatment course for up to 2 years after transplantation were evaluated, and cost-effectiveness was assessed from the payer's perspective. Main results: Of these 50 cases, 35 were treated with CST and 15 were treated with RIST. The mean survival time was 1.5 years in CST and 1.2 years in RIST, while the mean total cost per patient within the first 2 years was 29,630 for CST and 29,466 for RIST, with no significant difference. The duration of total hospitalization was shorter in RIST than in CST; then, the cost for hospitalization represented a lower proportion of the total cost in RIST (49% of total cost) than in CST (63%). In contrast, the cost related to the conditioning regimen was significantly higher in RIST than in CST. Conclusions: This result suggests that the increased cost of the conditioning regimen offsets the reduced cost of hospitalization in RIST. Although some differences were observed in the details of the cost, the total cost and mean survival were comparable between CST and RIST, and this result was confirmed by a probabilistic sensitivity analysis.

KW - Allogeneic stem cell transplantation (allo-SCT)

KW - Cost-effective analysis (CEA)

KW - Medical economics

UR - http://www.scopus.com/inward/record.url?scp=78349304888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78349304888&partnerID=8YFLogxK

U2 - 10.1007/s00520-009-0779-z

DO - 10.1007/s00520-009-0779-z

M3 - Article

VL - 18

SP - 1565

EP - 1569

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 12

ER -